<?xml version="1.0" encoding="System"?>
<results>
    <query>
        SELECT gpl, gsm, series_id, characteristics_ch1, organism_ch2, characteristics_ch2, description 
        FROM gsm where (organism_ch1 = 'Homo sapiens' OR organism_ch2 = 'Homo sapiens') 
         and (characteristics_ch1 like '%alive%' 
          or characteristics_ch1 like '%overall%'
          or characteristics_ch1 like '%follow%'
          or characteristics_ch1 like '%month%'
          or characteristics_ch2 like '%alive%' 
          or characteristics_ch2 like '%overall%'
          or characteristics_ch2 like '%follow%'
          or characteristics_ch2 like '%month%')
          and NOT (characteristics_ch1 like '%time%' 
           or characteristics_ch1 like '%clinical%' 
           or characteristics_ch1 like '%death%' 
           or characteristics_ch1 like '%survival%' 
           or characteristics_ch1 like '%age%' 
           or characteristics_ch1 like '%censor%' 
           or characteristics_ch1 like '%priva%' 
           or characteristics_ch2 like '%time%' 
           or characteristics_ch2 like '%death%' 
           or characteristics_ch2 like '%survival%' 
           or characteristics_ch2 like '%age%' 
           or characteristics_ch2 like '%clinical%' 
           or characteristics_ch2 like '%censor%' 
           or characteristics_ch2 like '%priva%')
    </query>
    <columns>
        <column>
            <displayName>gpl</displayName>
            <name>gpl</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
        <column>
            <displayName>gsm</displayName>
            <name>gsm</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
        <column>
            <displayName>series_id</displayName>
            <name>series_id</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
        <column>
            <displayName>characteristics_ch1</displayName>
            <name>characteristics_ch1</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
        <column>
            <displayName>organism_ch2</displayName>
            <name>organism_ch2</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
        <column>
            <displayName>characteristics_ch2</displayName>
            <name>characteristics_ch2</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
        <column>
            <displayName>description</displayName>
            <name>description</name>
            <table>gsm</table>
            <database></database>
            <type>TEXT</type>
        </column>
    </columns>
    <rows>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84231</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84244</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84247</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84250</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84251</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84252</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84253</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84254</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84255</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84256</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84257</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84258</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84259</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84260</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84261</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84262</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84263</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84264</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84265</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84266</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84267</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84268</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84269</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84270</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84271</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84272</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84273</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84274</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3091</value>
            <value column="1">GSM84275</value>
            <value column="2">GSE3642</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87961</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87962</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87963</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87964</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87965</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87966</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87967</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87968</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87969</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87970</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87971</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87972</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87973</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87974</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87975</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87976</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87977</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87978</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87979</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87980</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87981</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87982</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87983</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87984</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87985</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87986</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87987</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87988</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87989</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87990</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87991</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87992</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87993</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87994</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87995</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87996</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87997</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87998</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM87999</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM88000</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM88001</value>
            <value column="2">GSE3838,GSE8914</value>
            <value column="3">Megakaryoblastic cell line (Witte et al., Cancer 1986; 58(2):238-44), origin male 17-month old with megakaryoblastic leukemia</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Pooled RNA from 10 human cell lines</value>
            <value column="6">CHRF-288 model of megakaryocyte differentiation</value>
        </row>
        <row>
            <value column="0">GPL3038</value>
            <value column="1">GSM88762</value>
            <value column="2">GSE3886,GSE4385</value>
            <value column="3">Common Reference G (CRG)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">SSc6 fibroblasts Isolate B, Forearm (44/F with SSc x 6 months)</value>
            <value column="6">Simple annotation: scleroderma, cell line;	Image: http://smd.stanford.edu/MicroArray/gifs/2001-01/13221.gif</value>
        </row>
        <row>
            <value column="0">GPL3038</value>
            <value column="1">GSM88771</value>
            <value column="2">GSE3886,GSE4385</value>
            <value column="3">Common Reference G (CRG)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">SSc6 fibroblasts, Forearm (44/F with SSc x 6 months)</value>
            <value column="6">Simple annotation: scleroderma, cell line;	Image: http://smd.stanford.edu/MicroArray/gifs/2001-01/13227.gif</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96795</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96796</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96797</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96798</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96799</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96800</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96801</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96802</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL3455</value>
            <value column="1">GSM96803</value>
            <value column="2">GSE4244</value>
            <value column="3">Single-cell gDNA following Phi29 whole genome amplification</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Reference genomic DNA</value>
            <value column="6">Analysis Phi29 amplified single-cell gDNA versus non-amplified gDNA</value>
        </row>
        <row>
            <value column="0">GPL2040</value>
            <value column="1">GSM121588</value>
            <value column="2">GSE5326</value>
            <value column="3">Amplicon of unmethylated CpG islands prepared using McrBC restriction enzyme (spiked).</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Genomic DNA was digested using MseI then ligated to linker followed by a linker PCR of the all MseI fragments (spiked).</value>
            <value column="6">This experiment was designed to assess the levels of methylation of the CpG islands within the colorectal cell line HCT116.</value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM171833</value>
            <value column="2">GSE7132</value>
            <value column="3">tumor-conditioned HUVEC treated with 5-aza-2'deoxycytidine (200 nM) for 48 hrs, followed by treatment with 300 nM trichostatin A for 24 hrs.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tumor-conditioned HUVEC</value>
            <value column="6">the basic measure of RNA abundance was taken to be the mean intensity over pixels in the identified signal area</value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM171834</value>
            <value column="2">GSE7132</value>
            <value column="3">tumor-conditioned HUVEC</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tumor-conditioned HUVEC treated with 200 nM 5-aza-2'deoxycytidine for 48 hrs, followed by treatment with 300 nM trichostatin A for 24 hrs.</value>
            <value column="6">the basic measure of RNA abundance was taken to be the mean intensity over pixels in the identified signal area</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216795</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216796</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216797</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216798</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, unfavorable MRD, NOTCH wild-type,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216799</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216800</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216802</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216803</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216804</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216805</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216806</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216807</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216808</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216809</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216810</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216811</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216812</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, prednisone response N/A, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216813</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216814</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216815</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216816</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216817</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216818</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216819</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, prednisone response N/A, unfavorable MRD, NOTCH wild-type,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216820</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216821</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, prednisone response N/A, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216822</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216823</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216824</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216825</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216826</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216827</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216829</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216830</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216831</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216832</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216833</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, favorable MRD, NOTCH mutation,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216834</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216835</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216836</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216837</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216838</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216839</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216840</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, unfavorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216841</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216842</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216843</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, prednisone response N/A, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216844</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216845</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216846</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, unfavorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216847</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, prednisone response N/A, favorable MRD, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216848</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, favorable MRD, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216849</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, MRD N/A, NOTCH wild-type,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216850</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216851</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216852</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216853</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216855</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216856</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216857</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216858</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216859</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216860</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, MRD N/A, NOTCH wild-type,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216861</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216862</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216863</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216864</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH mutation, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216865</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216866</value>
            <value column="2">GSE8738</value>
            <value column="3">female patient, poor prednisone response, MRD N/A, NOTCH wild-type,  relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216868</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216870</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216871</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, poor prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5713</value>
            <value column="1">GSM216872</value>
            <value column="2">GSE8738</value>
            <value column="3">male patient, good prednisone response, MRD N/A, NOTCH wild-type, no relapse within follow-up period</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pooled DNA from peripheral blood mononuclear cells of ten healthy donors</value>
            <value column="6">Comparison of tumor DNA (Cy3-labeled) vs. normal DNA (Cy5-labeled). Whole-genome screening of DNA copy-number aberrations using array-CGH</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218969</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 6 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218974</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 6 one month after the treatment</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218979</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 12 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218984</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 12 one month after the treatment</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218985</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 19 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218989</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 19 one month after the treatment</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218995</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 56 one month after the treatment</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218997</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 56 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM218999</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 57-4 one month after the treatment</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219003</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 57 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219068</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 49 one month after the treatment.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219071</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 49 one month after the treatment.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219076</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 8 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219077</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 21 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219399</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 8 one month after the treatment.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219411</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 31 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219420</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 31 one month after the treatment</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219424</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 38 one month after the treatment</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219430</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 38 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy;	total array;	b) Normalization algorithm ;	Lowess (local weighted regression), </value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219448</value>
            <value column="2">GSE8833</value>
            <value column="3">Patient 45 one month after the treatment</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL5354</value>
            <value column="1">GSM219449</value>
            <value column="2">GSE8833</value>
            <value column="3">Blood samples from 11 women with benign gynecological diseases at out-patient clinic served as normal control individuals. Pooled RNA from these samples was used as a common reference for microarray analyses.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Patient 45 one month after the treatment.</value>
            <value column="6">a) Normalization strategy total array b) Normalization algorithm Lowess (local weighted regression),</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228554</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228555</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228560</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228561</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228691</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228694</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228697</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228698</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228699</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL3942</value>
            <value column="1">GSM228700</value>
            <value column="2">GSE9007,GSE9157</value>
            <value column="3">Subcutaneous WAT of obese subjects before bariatric surgery</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Subcutaneous WAT of obese subjects 3 months after bariatric surgery</value>
            <value column="6">Seventeen Caucasian morbidly obese women undergoing laparoscopic Roux-en-Y bypass were enrolled at Hotel Dieu Hospital, Paris, France. To study the effects of weight loss on scWAT gene expression, we processed 10 high-quality RNAs from scWAT biopsies of the 17 collected before/after bypass by cDNA microarray technique.</value>
        </row>
        <row>
            <value column="0">GPL5981</value>
            <value column="1">GSM236392</value>
            <value column="2">GSE9285</value>
            <value column="3">63 yo WF, 6 months of dSSc</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pool of RNA from 10 different human cell lines</value>
            <value column="6">NA</value>
        </row>
        <row>
            <value column="0">GPL5981</value>
            <value column="1">GSM236393</value>
            <value column="2">GSE9285</value>
            <value column="3">63 yo WF, 6 months of dSSc</value>
            <value column="4">Homo sapiens</value>
            <value column="5">pool of RNA from 10 different human cell lines</value>
            <value column="6">NA</value>
        </row>
        <row>
            <value column="0">GPL4868</value>
            <value column="1">GSM237706</value>
            <value column="2">GSE9334</value>
            <value column="3">The common reference cRNA sample comprised equal quantities of the following three components: (1) human umbilical cord endothelial cells (HUVEC), stimulated with TNF-alpha (50 microgram/ml, 6 hrs); (2) THP-1 cell line stimulated for 24 hours with phorbyl myristate (PMA, 100 microgram /ml), and subsequently for 6 hours with lipopolysaccharide (LPS, 1 microgram /ml), and (3) a mix of whole mount human aorta and iliac artery.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">HUVEC, grown to sub-confluency in T80 plates.</value>
            <value column="6">See the methods section of the linked publication for additional information</value>
        </row>
        <row>
            <value column="0">GPL4868</value>
            <value column="1">GSM237707</value>
            <value column="2">GSE9334</value>
            <value column="3">The common reference cRNA sample comprised equal quantities of the following three components: (1) human umbilical cord endothelial cells (HUVEC), stimulated with TNF-alpha (50 microgram/ml, 6 hrs); (2) THP-1 cell line stimulated for 24 hours with phorbyl myristate (PMA, 100 microgram /ml), and subsequently for 6 hours with lipopolysaccharide (LPS, 1 microgram /ml), and (3) a mix of whole mount human aorta and iliac artery.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">HUVEC, grown to sub-confluency in T80 plates.</value>
            <value column="6">See the methods section of the linked publication for additional information</value>
        </row>
        <row>
            <value column="0">GPL4868</value>
            <value column="1">GSM237708</value>
            <value column="2">GSE9334</value>
            <value column="3">The common reference cRNA sample comprised equal quantities of the following three components: (1) human umbilical cord endothelial cells (HUVEC), stimulated with TNF-alpha (50 microgram/ml, 6 hrs); (2) THP-1 cell line stimulated for 24 hours with phorbyl myristate (PMA, 100 microgram /ml), and subsequently for 6 hours with lipopolysaccharide (LPS, 1 microgram /ml), and (3) a mix of whole mount human aorta and iliac artery.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">HUVEC, grown to sub-confluency in T80 plates.</value>
            <value column="6">See the methods section of the linked publication for additional information</value>
        </row>
        <row>
            <value column="0">GPL4868</value>
            <value column="1">GSM237710</value>
            <value column="2">GSE9334</value>
            <value column="3">The common reference cRNA sample comprised equal quantities of the following three components: (1) human umbilical cord endothelial cells (HUVEC), stimulated with TNF-alpha (50 microgram/ml, 6 hrs); (2) THP-1 cell line stimulated for 24 hours with phorbyl myristate (PMA, 100 microgram /ml), and subsequently for 6 hours with lipopolysaccharide (LPS, 1 microgram /ml), and (3) a mix of whole mount human aorta and iliac artery.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">HUVEC grown to confluency</value>
            <value column="6">See the methods section of the linked publication for additional information</value>
        </row>
        <row>
            <value column="0">GPL4868</value>
            <value column="1">GSM237711</value>
            <value column="2">GSE9334</value>
            <value column="3">The common reference cRNA sample comprised equal quantities of the following three components: (1) human umbilical cord endothelial cells (HUVEC), stimulated with TNF-alpha (50 microgram/ml, 6 hrs); (2) THP-1 cell line stimulated for 24 hours with phorbyl myristate (PMA, 100 microgram /ml), and subsequently for 6 hours with lipopolysaccharide (LPS, 1 microgram /ml), and (3) a mix of whole mount human aorta and iliac artery.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">HUVEC grown to confluency</value>
            <value column="6">See the methods section of the linked publication for additional information</value>
        </row>
        <row>
            <value column="0">GPL4868</value>
            <value column="1">GSM237712</value>
            <value column="2">GSE9334</value>
            <value column="3">The common reference cRNA sample comprised equal quantities of the following three components: (1) human umbilical cord endothelial cells (HUVEC), stimulated with TNF-alpha (50 microgram/ml, 6 hrs); (2) THP-1 cell line stimulated for 24 hours with phorbyl myristate (PMA, 100 microgram /ml), and subsequently for 6 hours with lipopolysaccharide (LPS, 1 microgram /ml), and (3) a mix of whole mount human aorta and iliac artery.</value>
            <value column="4">Homo sapiens</value>
            <value column="5">HUVEC grown to confluency</value>
            <value column="6">See the methods section of the linked publication for additional information</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM248231</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right frontal glioblastoma of a 68 years old women. OS (months): 0.5. Died for thromboembolism</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249030</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right temporal glioblastoma of a 69 years old men. OS (months): 4.9</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249052</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right frontal glioblastoma of a 43 years old men. OS (months): 7.7</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249058</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right frontal-parietal glioblastoma of a 54 years old women. OS (months): 14.5</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249068</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right frontal glioblastoma of a 67 years old men. OS (months):1.6</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249084</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right parietal glioblastoma of a73 years old men. OS (months): 1.9</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249293</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from left frontal glioblastoma of a 53 years old men. OS (months): not available: lost during follow-up</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249297</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right temporal glioblastoma of a 66 years old women. OS (months): 19.8</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249298</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right frontal glioblastoma of a 67 years old men. OS (months): 0.4</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249299</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from  pilocytic astrocytoma of a 39 years old women. Alive (surgical resection: 09/03/1998)</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249300</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from a fibrillary astrocytoma  of a 29 years old men. Alive: (surgical resection: 06/01/1991)</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249301</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from a pilocytic astrocytoma  of a 7 years old child. Alive:  surgical resection 23/09/1996</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249302</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from a pilocytic astrocytoma   of a 20 years old men. Alive, surgical resection: 03/10/1991</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249303</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from a pilocytic astrocytoma  of a 26 years old women. Alive: surgical resection: 06/30/1991</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249304</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from a pilocytic astrocytoma of a 3 years old child. Alive, surgical resection: 05/15/1990</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249312</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from oligodendroglioma of a 60 years old women. Alive, surgical resection: 11/02/1999</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249313</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right frontal oligodendroglioma of a 60 years old men. Alive, surgical resection: 12/16/1999</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL885</value>
            <value column="1">GSM249315</value>
            <value column="2">GSE9885</value>
            <value column="3">Fresh frozen biopsy from right frontal glioblastoma of a 68 years old women. OS (months): 0.5</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from parietal fibrillary astrocytoma  of a 34 years old women. OS (months): 134</value>
            <value column="6">Fluorescent;	intensities on scanned images were quantified by the feature extraction;	software 7.5, and LogRatio data were available for further statistical;	analysis. </value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249357</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from right temporal glioblastoma of a 35 years old women. OS (months): 18.8</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249360</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from frontal-temporal glioblastoma of a 59 years old men. OS (months): 11.5</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL887</value>
            <value column="1">GSM249361</value>
            <value column="2">GSE9885</value>
            <value column="3">pool of 4 oligodendrogliomas(OL), 5 pilocytic astrocytomas (PA), 2 fibrillary astrocytomas (FA)</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Fresh frozen biopsy from left frontal glioblastoma (focal necrosis) of a 79 years old women. Alive, surgical resection: 03/04/2003</value>
            <value column="6">Fluorescent intensities on scanned images were quantified by the feature extraction software 7.5, and LogRatio data were available for further statistical analysis.</value>
        </row>
        <row>
            <value column="0">GPL6259</value>
            <value column="1">GSM253487</value>
            <value column="2">GSE11072</value>
            <value column="3">Quality metric=28S to 18: 2.02;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Second site: bone;	Marterial : primary cultures from tumor tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Quality metric=28S to 18: 1.98;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Presenting symptoms: no apparent symptoms;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Marterial : primary cultures from tumor tissues</value>
            <value column="6">Biological replicate 3 of 9. Clear cell renal cell carcinoma, metastasis and primary cells from tissues</value>
        </row>
        <row>
            <value column="0">GPL6259</value>
            <value column="1">GSM253494</value>
            <value column="2">GSE11072</value>
            <value column="3">Quality metric=28S to 18: 2.00;	Gender : Women;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Presenting symptoms: blood in urine;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Second site: lymph node near abdominal aorta;	Marterial : primary cultures from tumor tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Quality metric=28S to 18: 1.97;	Gender : Woman;	Ethnic background: Han;	Histology: clear cell renal cell carcinoma;	Marterial : primary cultures from tumor tissues</value>
            <value column="6">Biological replicate 8 of 9.  Metastasis vs non-metastasis, clear cell renal cell carcinoma, primary cultures from tumor tissues</value>
        </row>
        <row>
            <value column="0">GPL6259</value>
            <value column="1">GSM253495</value>
            <value column="2">GSE11072</value>
            <value column="3">Quality metric=28S to 18: 1.94;	Gender : Man;	Second site: bone;	Histology: clear cell renal cell carcinoma;	Marterial: primary culture from tumor tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Quality metric=28S to 18: 1.98;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Presenting symptoms: no signifacant symptoms;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Marterial : primary cultures from tumor tissues</value>
            <value column="6">Biological replicate 6 of 9.  Metastasis vs non-metastasis, clear cell renal cell carcinoma, primary cultures from tumor tissues</value>
        </row>
        <row>
            <value column="0">GPL6259</value>
            <value column="1">GSM253496</value>
            <value column="2">GSE11072</value>
            <value column="3">Quality metric=28S to 18: 1.94;	Gender : Man;	Second site: bone;	Histology: clear cell renal cell carcinoma;	Marterial: primary culture from tumor tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Quality metric=28S to 18: 1.98;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Presenting symptoms: no apparent symptoms;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Marterial : primary cultures from tumor tissues</value>
            <value column="6">Biological replicate 5 of 9.  Metastasis vs non-metastasis, clear cell renal cell carcinoma, primary cultures from tumor tissues</value>
        </row>
        <row>
            <value column="0">GPL6259</value>
            <value column="1">GSM253497</value>
            <value column="2">GSE11072</value>
            <value column="3">TriZol procedure;	Quality metric=28S to 18: 2.00;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month ;	Presenting symptoms: blood in urine;	Diagnosis made by: CT and pathology;	TNM:1,2,0;	Histology: clear cell renal cell carcinoma;	Second site: lymph node near abdominal aorta;	Marterial : primary cultures from tumor tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Quality metric=28S to 18: 1.97;	Histology: clear cell renal cell carcinoma;	Marterial : primary cultures from tumor tissues</value>
            <value column="6">Biological replicate 7 of 9.  Metastasis vs non-metastasis, clear cell renal cell carcinoma, primary cultures from tumor tissues</value>
        </row>
        <row>
            <value column="0">GPL6259</value>
            <value column="1">GSM253498</value>
            <value column="2">GSE11072</value>
            <value column="3">Quality metric=28S to 18: 2.02;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Second site: bone;	Marterial : primary cultures from tumor tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">Quality metric=28S to 18: 1.98;	Gender : Man;	Ethnic background: Han;	Days from patient diagnosis to excison: 1 month;	Presenting symptoms: no apparent symptoms;	Diagnosis made by: CT and pathology;	Histology: clear cell renal cell carcinoma;	Marterial : primary cultures from tumor tissues</value>
            <value column="6">Biological replicate 4 of 9. Metastasis vs non-metastasis, clear cell renal cell carcinoma, primary cultures from tumor tissues</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282855</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 101;	current medication: Paracetamol;	birth date: 10/5/63;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/2/04;	indictation for procedure: Weight loss, altered bowel habbit.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282856</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 102;	current medication: Movicol 1 sachet daily;	birth date: 9/5/62;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/2/04;	indictation for procedure: RIF pain, persistent anaemia.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282857</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 103;	current medication: None;	birth date: 6/30/65;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/9/04;	indictation for procedure: Diarrhoea, now settled, Mum has UC;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282858</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 105;	current medication: None;	birth date: 7/29/84;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282859</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 105;	current medication: None;	birth date: 7/29/84;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282860</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 106;	current medication: None;	birth date: 5/29/87;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/18/04;	indictation for procedure: Abdominal pain, upper GI symptoms.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282861</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 108;	current medication: Asacol 400mg BD;	birth date: 8/30/33;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/25/04;	indictation for procedure: Altered bowel habbit, ? UC 1974, never on Bx.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282862</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 104;	current medication: None;	birth date: 1/2/72;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282863</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 107;	current medication: None;	birth date: 07/28/1060;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/25/04;	indictation for procedure: FH Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282864</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 109;	current medication: None;	birth date: 10/10/57;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: FH of Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282865</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 110;	current medication: None;	birth date: 3/13/54;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: Diarrhoea;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282866</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 111;	current medication: Paracetamol;	birth date: 9/5/82;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/3/04;	indictation for procedure: FH of CD, Path Increased lymphiod in TI Bx.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282867</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 112;	current medication: None;	birth date: 7/5/81;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/7/04;	indictation for procedure: Altered bowel habit;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282868</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 113;	current medication: OCP;	birth date: 8/17/81;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/14/04;	indictation for procedure: Recurrant abcess, ?IBD;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282869</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 114;	current medication: None;	birth date: 6/27/36;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/14/04;	indictation for procedure: Altered bowel habit, Alcohol excess;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282870</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 115;	current medication: Frusemide, Codine Phosphate;	birth date: 9/14/28;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: Diarrhoea, Also has Prostate Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282871</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 116;	current medication: Clomiprimine;	birth date: 1/19/56;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: FH Colon cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282872</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 117;	current medication: Loperamide;	birth date: 3/31/67;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282873</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 101;	current medication: Paracetamol;	birth date: 10/5/63;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/2/04;	indictation for procedure: Weight loss, altered bowel habbit.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282874</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 104;	current medication: None;	birth date: 1/2/72;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282875</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 110;	current medication: None;	birth date: 3/13/54;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: Diarrhoea;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282876</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 101;	current medication: Paracetamol;	birth date: 10/5/63;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/2/04;	indictation for procedure: Weight loss, altered bowel habbit.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282877</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 103;	current medication: None;	birth date: 6/30/65;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/9/04;	indictation for procedure: Diarrhoea, now settled, Mum has UC;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282878</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 104;	current medication: None;	birth date: 1/2/72;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282879</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 105;	current medication: None;	birth date: 7/29/84;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282880</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 106;	current medication: None;	birth date: 5/29/87;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/18/04;	indictation for procedure: Abdominal pain, upper GI symptoms.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282881</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 107;	current medication: None;	birth date: 07/28/1060;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/25/04;	indictation for procedure: FH Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282882</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 102;	current medication: Movicol 1 sachet daily;	birth date: 9/5/62;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/2/04;	indictation for procedure: RIF pain, persistent anaemia.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282883</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 109;	current medication: None;	birth date: 10/10/57;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: FH of Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282884</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 110;	current medication: None;	birth date: 3/13/54;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: Diarrhoea;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282885</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 111;	current medication: Paracetamol;	birth date: 9/5/82;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/3/04;	indictation for procedure: FH of CD, Path Increased lymphiod in TI Bx.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282886</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 112;	current medication: None;	birth date: 7/5/81;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/7/04;	indictation for procedure: Altered bowel habit;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282887</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 114;	current medication: None;	birth date: 6/27/36;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/14/04;	indictation for procedure: Altered bowel habit, Alcohol excess;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282888</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 115;	current medication: Frusemide, Codine Phosphate;	birth date: 9/14/28;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: Diarrhoea, Also has Prostate Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282889</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 116;	current medication: Clomiprimine;	birth date: 1/19/56;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: FH Colon cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282890</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 117;	current medication: Loperamide;	birth date: 3/31/67;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282891</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 103;	current medication: None;	birth date: 6/30/65;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/9/04;	indictation for procedure: Diarrhoea, now settled, Mum has UC;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282892</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 104;	current medication: None;	birth date: 1/2/72;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282893</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 105;	current medication: None;	birth date: 7/29/84;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/15/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282894</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 107;	current medication: None;	birth date: 07/28/1060;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/25/04;	indictation for procedure: FH Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282895</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 109;	current medication: None;	birth date: 10/10/57;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: FH of Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282896</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 110;	current medication: None;	birth date: 3/13/54;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/2/04;	indictation for procedure: Diarrhoea;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282897</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 111;	current medication: Paracetamol;	birth date: 9/5/82;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/3/04;	indictation for procedure: FH of CD, Path Increased lymphiod in TI Bx.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282898</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 112;	current medication: None;	birth date: 7/5/81;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/7/04;	indictation for procedure: Altered bowel habit;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282899</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 114;	current medication: None;	birth date: 6/27/36;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/14/04;	indictation for procedure: Altered bowel habit, Alcohol excess;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282900</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 115;	current medication: Frusemide, Codine Phosphate;	birth date: 9/14/28;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: Diarrhoea, Also has Prostate Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282901</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 117;	current medication: Loperamide;	birth date: 3/31/67;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/21/04;	indictation for procedure: IBS type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282902</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 119;	current medication: Salubtamol, Bricanyl;	birth date: 9/30/70;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/27/05;	indictation for procedure: FH Colon Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282903</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 120;	current medication: Minicycline;	birth date: 5/6/54;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/18/05;	indictation for procedure: Altered bowel habit;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282904</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 120;	current medication: Minicycline;	birth date: 5/6/54;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/18/05;	indictation for procedure: Altered bowel habit;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282905</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 121;	current medication: Cp-tenedone, Enalapril, Loperamide.;	birth date: 4/8/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/1/05;	indictation for procedure: Diarrhoea, Blastocytitis on stool cultures.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282906</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 121;	current medication: Cp-tenedone, Enalapril, Loperamide.;	birth date: 4/8/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/1/05;	indictation for procedure: Diarrhoea, Blastocytitis on stool cultures.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282907</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 121;	current medication: Cp-tenedone, Enalapril, Loperamide.;	birth date: 4/8/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/1/05;	indictation for procedure: Diarrhoea, Blastocytitis on stool cultures.;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282908</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 122;	current medication: Venlafaxine;	birth date: 7/10/61;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/10/05;	indictation for procedure: FH Colon Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282909</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 122;	current medication: Venlafaxine;	birth date: 7/10/61;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/10/05;	indictation for procedure: FH Colon Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282910</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 122;	current medication: Venlafaxine;	birth date: 7/10/61;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/10/05;	indictation for procedure: FH Colon Ca;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282911</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 124;	current medication: OCP;	birth date: 6/25/77;	gender: F;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: IBS Type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282912</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 124;	current medication: OCP;	birth date: 6/25/77;	gender: F;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: IBS Type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282913</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 124;	current medication: OCP;	birth date: 6/25/77;	gender: F;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: IBS Type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282914</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 125;	current medication: OCP;	birth date: 3/17/78;	gender: F;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: Diarrhoea predominant IBS;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282915</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 125;	current medication: OCP;	birth date: 3/17/78;	gender: F;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: Diarrhoea predominant IBS;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282916</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 126;	current medication: None;	birth date: 4/4/87;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: FH of Crohn's disease, Symtom free at procedure;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282917</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 127;	current medication: Prednisolone 10mg Heparin Questran Gabapentin FA;	birth date: 9/9/36;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/29/05;	indictation for procedure: Pseudomembranous Colitis;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282918</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 128;	current medication: Pentaza;	birth date: 3/19/81;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/1/05;	indictation for procedure: IBS Type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282919</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 128;	current medication: Pentaza;	birth date: 3/19/81;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/1/05;	indictation for procedure: IBS Type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282920</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 126;	current medication: None;	birth date: 4/4/87;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/1/05;	indictation for procedure: FH of Crohn's disease, Symtom free at procedure;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282921</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 128;	current medication: Pentaza;	birth date: 3/19/81;	gender: M;	ethnicity: JEWISH;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/1/05;	indictation for procedure: IBS Type symptoms;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282922</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 134;	current medication: None;	birth date: 12/21/50;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/12/05;	indictation for procedure: Abdominal pain;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282923</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 135;	current medication: none;	birth date: 8/14/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/28/05;	indictation for procedure: bloody diahorrea;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282924</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 135;	current medication: none;	birth date: 8/14/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/28/05;	indictation for procedure: bloody diahorrea;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: TRUE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282925</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 136;	current medication: metranidazole 400mg TDS Prednisolone;	birth date: 5/21/51;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/20/05;	indictation for procedure: Diarrhoea PR bleeding;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282926</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 136;	current medication: metranidazole 400mg TDS Prednisolone;	birth date: 5/21/51;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/20/05;	indictation for procedure: Diarrhoea PR bleeding;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282927</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 133;	current medication: Omeprazole 20mg;	birth date: 4/23/65;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: ;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/13/05;	indictation for procedure: FH Colon Cancer;	ucss: 0;	calprotectin: ;	esr: ;	crp: ;	hb: ;	wcc: ;	neutrophils: ;	albumin: ;	blood obtained: FALSE;	ibd affected relatives: ;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: ;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: ;	category: 0;	smoking status: ;	smoking start date: ;	smoking stop date: ;	smoking amount: ;	other illnesses: ;	disease: Normal;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">Normal Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282928</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 205;	current medication: Pentaza 3g/d;	birth date: 6/8/79;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 10/1/03;	diagnosis date: 8/30/04;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/8/04;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 15;	crp: 19;	hb: 110;	wcc: 5;	neutrophils: 3;	albumin: 43;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/8/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: NEW;	smoking status: ex;	smoking start date: 1/1/85;	smoking stop date: 3/1/03;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: terminal ileum;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282929</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 229;	current medication: Naproxen;	birth date: 11/27/61;	gender: unknown;	ethnicity: CAUCASIAN;	symptoms onset date: 1/14/05;	diagnosis date: 1/18/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/18/05;	indictation for procedure: ;	ucss: 6;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 3/26/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 7/7/05;	category: NEW;	smoking status: unknown;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282930</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 205;	current medication: Pentaza 3g/d;	birth date: 6/8/79;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 10/1/03;	diagnosis date: 8/30/04;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/8/04;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 15;	crp: 19;	hb: 110;	wcc: 5;	neutrophils: 3;	albumin: 43;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/8/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: NEW;	smoking status: ex;	smoking start date: 1/1/85;	smoking stop date: 3/1/03;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282931</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 205;	current medication: Pentaza 3g/d;	birth date: 6/8/79;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 10/1/03;	diagnosis date: 8/30/04;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/8/04;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 15;	crp: 19;	hb: 110;	wcc: 5;	neutrophils: 3;	albumin: 43;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/8/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: NEW;	smoking status: ex;	smoking start date: 1/1/85;	smoking stop date: 3/1/03;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282932</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 238;	current medication: Enalapril Zantac;	birth date: 9/27/38;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 9/25/03;	diagnosis date: 1/14/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: NEW;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/03;	smoking amount: 5-14;	other illnesses: Hypertension Diverticular disease;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282933</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 238;	current medication: Enalapril Zantac;	birth date: 9/27/38;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 9/25/03;	diagnosis date: 1/14/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: NEW;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/03;	smoking amount: 5-14;	other illnesses: Hypertension Diverticular disease;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282934</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 243;	current medication: Atenolol Pravastatin Asprin Adalat BFZ Balsalizide;	birth date: 2/17/25;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 8/1/04;	diagnosis date: 3/29/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/29/05;	indictation for procedure: ;	ucss: 5;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/29/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 6/1/05;	category: NEW;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: IHD Deaf;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282935</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 245;	current medication: Pentaza 1g BD;	birth date: 11/4/67;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 11/4/04;	diagnosis date: 3/16/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/16/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 3/16/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 6/3/05;	category: NEW;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Asthma;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282936</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 251;	current medication: Bumetanide Asprin Lisinopril Colifoam;	birth date: 5/22/21;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/05;	diagnosis date: 6/6/05;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/6/05;	indictation for procedure: ;	ucss: 9;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 7/7/05;	category: NEW;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Vaginal Prolapse-Angina;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282937</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 256;	current medication: None;	birth date: 10/16/44;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 4/1/05;	diagnosis date: 6/2/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/2/05;	indictation for procedure: ;	ucss: 10;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: unknown;	last followup date: 6/2/05;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 9/14/05;	category: NEW;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282938</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 270;	current medication: Becotide inhaler;	birth date: 4/30/52;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/99;	diagnosis date: 8/24/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 8/24/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 8/24/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 9/14/05;	category: NEW;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 5-14;	other illnesses: Asthma;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282939</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 201;	current medication: None;	birth date: 4/12/56;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 6/19/03;	diagnosis date: 7/4/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 9/30/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 9/30/04;	followup rectum: BOTH;	followup recto sigmoid: HISTOLOGICAL;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/7/04;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: 1/1/70;	smoking stop date: 1/1/99;	smoking amount: 25+;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282940</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 201;	current medication: None;	birth date: 4/12/56;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 6/19/03;	diagnosis date: 7/4/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 9/30/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 9/30/04;	followup rectum: BOTH;	followup recto sigmoid: HISTOLOGICAL;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/7/04;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: 1/1/70;	smoking stop date: 1/1/99;	smoking amount: 25+;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282941</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 202;	current medication: Sulphasalazine 3g/d, Folic Acid 5mg/d, HRT, DF118;	birth date: 10/3/50;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/68;	diagnosis date: 1/1/69;	joint problems: TRUE;	uc flare up: TRUE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 9/30/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 9/30/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Polymyalgia rheumatica;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282942</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 203;	current medication: Asacol 800mg BD, Simvastatin;	birth date: 1/10/35;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 11/1/92;	diagnosis date: 3/23/93;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/1/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 14;	crp: 0;	hb: 147;	wcc: 6;	neutrophils: 4;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: HISTOLOGICAL;	diagnosis recto sigmoid: HISTOLOGICAL;	diagnosis splen flex: HISTOLOGICAL;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/1/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/50;	smoking stop date: 1/1/57;	smoking amount: 25+;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282943</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 206;	current medication: Asacol 800mg BD;	birth date: 9/10/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/1/80;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/8/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 2;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/8/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/94;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282944</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 207;	current medication: Asacol 800mg BD, Colifoam Enemas Daily;	birth date: 4/29/47;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/88;	diagnosis date: 8/18/88;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/14/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 10/14/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/10/62;	smoking stop date: 3/15/75;	smoking amount: 25+;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282945</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 208;	current medication: Prednisolone 25mg/d, Pentaza 1g BD, Fosomax weekly;	birth date: 8/16/85;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 6/1/04;	diagnosis date: 6/25/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/14/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 17;	crp: 3;	hb: 121;	wcc: 8;	neutrophils: 5;	albumin: 39;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/14/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282946</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 210;	current medication: Mesalazine 800mg B, Prednisolone Supps;	birth date: 6/28/56;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/73;	diagnosis date: 1/10/74;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/19/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/14/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Scarlet Fever 1964;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282947</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 211;	current medication: Predfoam Adcal D3 Alendronate;	birth date: 11/10/44;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/77;	diagnosis date: 6/7/79;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/5/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/5/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Coeliac disease 1991;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282948</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 213;	current medication: PRED 7MG, ATENOLOL 100MG, ASPRIN 75MG, SIMVASTATI;	birth date: 11/1/43;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/82;	diagnosis date: 2/2/83;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/12/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/12/04;	followup rectum: COLONOSCOPIC;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/74;	smoking amount: unknown;	other illnesses: ISCHEAMIC HEART DISEASE;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282949</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 216;	current medication: NONE;	birth date: 5/10/36;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/19/66;	diagnosis date: 8/20/66;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/18/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 11;	igr2230: 11;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/18/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: NONE;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282950</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 217;	current medication: Asacol 1.2g daily;	birth date: 2/9/57;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/10/79;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/26/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/26/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282951</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 218;	current medication: Sulphasalazine Asprin Metoprolol Atorvastatin;	birth date: 9/27/24;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/58;	diagnosis date: 1/1/58;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/3/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/3/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Breast cancer;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282952</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 219;	current medication: Sulphasalazine 1.2g Colifoam;	birth date: 1/5/43;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/81;	diagnosis date: 1/1/81;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/7/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/7/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282953</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 220;	current medication: Asacol 800mg BFZ 2.5mg Metformin Simvastatin;	birth date: 6/28/48;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/10/95;	diagnosis date: 3/25/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/10/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 12/10/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/90;	smoking amount: 5-14;	other illnesses: Type 2 DM.;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282954</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 223;	current medication: Prednisolone 20mg Asacol 2.4g;	birth date: 1/18/44;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/04;	diagnosis date: 3/15/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/16/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/16/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: unknown;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282955</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 224;	current medication: Salazopyrin BFZ Losartan Thyroxine Doxazosin;	birth date: 2/21/38;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/77;	diagnosis date: 1/1/77;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 12;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Hypertension Hashimoto's Thyroditis;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282956</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 225;	current medication: Asacol;	birth date: 5/30/76;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/03;	diagnosis date: 6/2/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/99;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282957</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 206;	current medication: Asacol 800mg BD;	birth date: 9/10/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/1/80;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/8/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 2;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/8/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/94;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282958</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 210;	current medication: Mesalazine 800mg B, Prednisolone Supps;	birth date: 6/28/56;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/73;	diagnosis date: 1/10/74;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/19/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/14/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Scarlet Fever 1964;	disease: UC;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282959</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 228;	current medication: None;	birth date: 11/22/48;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/80;	diagnosis date: 1/1/82;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 1/14/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Migraines;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282960</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 233;	current medication: Asacol 1.2g Asprin 75mg Amilodipine 10mg;	birth date: 2/2/29;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/92;	diagnosis date: 1/1/92;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/1/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/1/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/86;	smoking amount: 15-24;	other illnesses: MI 1986, Prostate cancer 1994;	disease: UC;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282961</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 233;	current medication: Asacol 1.2g Asprin 75mg Amilodipine 10mg;	birth date: 2/2/29;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/92;	diagnosis date: 1/1/92;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/1/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/1/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/86;	smoking amount: 15-24;	other illnesses: MI 1986, Prostate cancer 1994;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282962</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 202;	current medication: Sulphasalazine 3g/d, Folic Acid 5mg/d, HRT, DF118;	birth date: 10/3/50;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/68;	diagnosis date: 1/1/69;	joint problems: TRUE;	uc flare up: TRUE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 9/30/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 9/30/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Polymyalgia rheumatica;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282963</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 203;	current medication: Asacol 800mg BD, Simvastatin;	birth date: 1/10/35;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 11/1/92;	diagnosis date: 3/23/93;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/1/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 14;	crp: 0;	hb: 147;	wcc: 6;	neutrophils: 4;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: HISTOLOGICAL;	diagnosis recto sigmoid: HISTOLOGICAL;	diagnosis splen flex: HISTOLOGICAL;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/1/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/50;	smoking stop date: 1/1/57;	smoking amount: 25+;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282964</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 204;	current medication: AZA 200mg, Insulin, Asprin, Atenolol, Simvastatin;	birth date: 8/15/43;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 7/1/02;	diagnosis date: 8/1/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 11/1/04;	indictation for procedure: ;	ucss: 5;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 0;	nod 702: 0;	nod 908: 0;	dlg5 133a: 0;	nod 1007 fs: 0;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/1/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/16/04;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: 1/1/58;	smoking stop date: 1/1/01;	smoking amount: 25+;	other illnesses: Type 2 DM 02/2004.-Gout.;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282965</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 209;	current medication: AZA 150mg/d, Mesalazine 800mg TDS;	birth date: 3/27/80;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/89;	diagnosis date: 1/1/89;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 10/15/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/15/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 12/16/04;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 1-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282966</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 212;	current medication: Pred 10mg, AZA150mg, ADCAL D3;	birth date: 8/3/76;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/97;	diagnosis date: 9/1/01;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 11/9/04;	indictation for procedure: ;	ucss: 7;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 0;	igr2198: 11;	igr2230: 12;	octn1: 11;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/9/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/16/04;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282967</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 214;	current medication: NONE;	birth date: 1/10/37;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/59;	diagnosis date: 1/10/61;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/12/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 1;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 11/12/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 12/9/04;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: CENTRAL RETINAL VEIN OCCLUSION 01/04;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282968</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 215;	current medication: Prednisolone 5ng Balsalazide Lansoperazole;	birth date: 5/6/60;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/02;	diagnosis date: 8/16/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/16/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: unknown;	last followup date: 11/16/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/03;	smoking stop date: 1/1/04;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282969</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 221;	current medication: Prednisolone 7mg Asacol Adcal Seretide Fe SO4;	birth date: 1/29/86;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 12/10/01;	diagnosis date: 12/10/01;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/14/04;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 12/14/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Asthma Eczema;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282970</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 222;	current medication: Prednisolone 20mg Balsalazide;	birth date: 4/13/52;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 9/1/85;	diagnosis date: 6/20/86;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 12/16/04;	indictation for procedure: ;	ucss: 9;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/16/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 5-25-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282971</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 215;	current medication: Prednisolone 5ng Balsalazide Lansoperazole;	birth date: 5/6/60;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/02;	diagnosis date: 8/16/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/16/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: unknown;	last followup date: 11/16/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/03;	smoking stop date: 1/1/04;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 6-2-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282972</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 226;	current medication: Azathioprine 150mg Asacol 1.6g Ca Vit D B12;	birth date: 6/15/74;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/89;	diagnosis date: 1/1/89;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 1/11/05;	indictation for procedure: ;	ucss: 8;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/11/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282973</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 227;	current medication: Asacol Prednisolone 5 Omeprazole Warfarin Cal VitD;	birth date: 4/17/28;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/90;	diagnosis date: 1/1/90;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/14/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 1/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/72;	smoking amount: 5-14;	other illnesses: Prostate cancer 1985, Previous DVT's on warfarin;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282974</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 231;	current medication: prednisolone 40mg heparin clarithromycin;	birth date: 10/29/77;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 10/1/00;	diagnosis date: 11/19/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/28/05;	indictation for procedure: ;	ucss: 7;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 9/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 9/14/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282975</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 232;	current medication: Pentaza 2g BD;	birth date: 1/9/63;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/95;	diagnosis date: 1/1/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/31/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 1/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 6-2-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282976</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 204;	current medication: AZA 200mg, Insulin, Asprin, Atenolol, Simvastatin;	birth date: 8/15/43;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 7/1/02;	diagnosis date: 8/1/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 11/1/04;	indictation for procedure: ;	ucss: 5;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 0;	nod 702: 0;	nod 908: 0;	dlg5 133a: 0;	nod 1007 fs: 0;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/1/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/16/04;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: 1/1/58;	smoking stop date: 1/1/01;	smoking amount: 25+;	other illnesses: Type 2 DM 02/2004.-Gout.;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282977</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 215;	current medication: Prednisolone 5ng Balsalazide Lansoperazole;	birth date: 5/6/60;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/02;	diagnosis date: 8/16/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/16/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: unknown;	last followup date: 11/16/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/03;	smoking stop date: 1/1/04;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282978</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 226;	current medication: Azathioprine 150mg Asacol 1.6g Ca Vit D B12;	birth date: 6/15/74;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/89;	diagnosis date: 1/1/89;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 1/11/05;	indictation for procedure: ;	ucss: 8;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/11/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282979</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 232;	current medication: Pentaza 2g BD;	birth date: 1/9/63;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/95;	diagnosis date: 1/1/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/31/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 1/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282980</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 214;	current medication: NONE;	birth date: 1/10/37;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/59;	diagnosis date: 1/10/61;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/12/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 1;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 11/12/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 12/9/04;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: CENTRAL RETINAL VEIN OCCLUSION 01/04;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282981</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 215;	current medication: Prednisolone 5ng Balsalazide Lansoperazole;	birth date: 5/6/60;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/02;	diagnosis date: 8/16/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/16/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: unknown;	last followup date: 11/16/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/03;	smoking stop date: 1/1/04;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282982</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 221;	current medication: Prednisolone 7mg Asacol Adcal Seretide Fe SO4;	birth date: 1/29/86;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 12/10/01;	diagnosis date: 12/10/01;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/14/04;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 12/14/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Asthma Eczema;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282983</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 226;	current medication: Azathioprine 150mg Asacol 1.6g Ca Vit D B12;	birth date: 6/15/74;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/89;	diagnosis date: 1/1/89;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 1/11/05;	indictation for procedure: ;	ucss: 8;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/11/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282984</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 227;	current medication: Asacol Prednisolone 5 Omeprazole Warfarin Cal VitD;	birth date: 4/17/28;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/90;	diagnosis date: 1/1/90;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/14/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 1/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/72;	smoking amount: 5-14;	other illnesses: Prostate cancer 1985, Previous DVT's on warfarin;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282985</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 231;	current medication: prednisolone 40mg heparin clarithromycin;	birth date: 10/29/77;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 10/1/00;	diagnosis date: 11/19/02;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/28/05;	indictation for procedure: ;	ucss: 7;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 9/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 9/14/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282986</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 232;	current medication: Pentaza 2g BD;	birth date: 1/9/63;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/95;	diagnosis date: 1/1/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/31/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 1/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282987</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 216;	current medication: NONE;	birth date: 5/10/36;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/19/66;	diagnosis date: 8/20/66;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/18/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 11;	igr2230: 11;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/18/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: NONE;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282988</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 217;	current medication: Asacol 1.2g daily;	birth date: 2/9/57;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/10/79;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/26/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/26/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282989</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 218;	current medication: Sulphasalazine Asprin Metoprolol Atorvastatin;	birth date: 9/27/24;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/58;	diagnosis date: 1/1/58;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/3/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/3/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Breast cancer;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282990</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 219;	current medication: Sulphasalazine 1.2g Colifoam;	birth date: 1/5/43;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/81;	diagnosis date: 1/1/81;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/7/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/7/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282991</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 220;	current medication: Asacol 800mg BFZ 2.5mg Metformin Simvastatin;	birth date: 6/28/48;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/10/95;	diagnosis date: 3/25/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/10/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 12/10/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/90;	smoking amount: 5-14;	other illnesses: Type 2 DM.;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282992</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 225;	current medication: Asacol;	birth date: 5/30/76;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/03;	diagnosis date: 6/2/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/99;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282993</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 224;	current medication: Salazopyrin BFZ Losartan Thyroxine Doxazosin;	birth date: 2/21/38;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/77;	diagnosis date: 1/1/77;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 12;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Hypertension Hashimoto's Thyroditis;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282994</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 228;	current medication: None;	birth date: 11/22/48;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/80;	diagnosis date: 1/1/82;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 1/14/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Migraines;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282995</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 230;	current medication: Asacol 1.6g/ day;	birth date: 12/27/57;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 3/12/02;	diagnosis date: 12/3/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/25/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/25/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: ? MS never proven;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282996</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 235;	current medication: Asacol Predfoam Lanzoprazole;	birth date: 1/9/47;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 6/24/97;	diagnosis date: 8/26/97;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/11/05;	indictation for procedure: ;	ucss: 5;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/11/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/31/05;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/97;	smoking amount: 15-24;	other illnesses: TURP;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282997</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 241;	current medication: Asacol 800mg bd Azathioprine 100mg;	birth date: 6/25/62;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 11/1/90;	diagnosis date: 11/11/91;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/10/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 22;	igr2198: 22;	igr2230: 22;	octn1: 22;	octn2: 22;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/10/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282998</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 241;	current medication: Asacol 800mg bd Azathioprine 100mg;	birth date: 6/25/62;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 11/1/90;	diagnosis date: 11/11/91;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/10/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 22;	igr2198: 22;	igr2230: 22;	octn1: 22;	octn2: 22;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/10/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM282999</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 241;	current medication: Asacol 800mg bd Azathioprine 100mg;	birth date: 6/25/62;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 11/1/90;	diagnosis date: 11/11/91;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/10/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 22;	igr2198: 22;	igr2230: 22;	octn1: 22;	octn2: 22;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/10/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283000</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 201;	current medication: None;	birth date: 4/12/56;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 6/19/03;	diagnosis date: 7/4/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 9/30/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 9/30/04;	followup rectum: BOTH;	followup recto sigmoid: HISTOLOGICAL;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/7/04;	category: FAILURE OF THERAPY;	smoking status: ex;	smoking start date: 1/1/70;	smoking stop date: 1/1/99;	smoking amount: 25+;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283001</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 206;	current medication: Asacol 800mg BD;	birth date: 9/10/59;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/1/80;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/8/04;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 2;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/8/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/94;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283002</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 210;	current medication: Mesalazine 800mg B, Prednisolone Supps;	birth date: 6/28/56;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/73;	diagnosis date: 1/10/74;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 10/19/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 10/14/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Scarlet Fever 1964;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283003</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 213;	current medication: PRED 7MG, ATENOLOL 100MG, ASPRIN 75MG, SIMVASTATI;	birth date: 11/1/43;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/82;	diagnosis date: 2/2/83;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/12/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/12/04;	followup rectum: COLONOSCOPIC;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/74;	smoking amount: unknown;	other illnesses: ISCHEAMIC HEART DISEASE;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283004</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 216;	current medication: NONE;	birth date: 5/10/36;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/19/66;	diagnosis date: 8/20/66;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/18/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 11;	igr2230: 11;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/18/04;	followup rectum: unknown;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 12/9/04;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: NONE;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283005</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 217;	current medication: Asacol 1.2g daily;	birth date: 2/9/57;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/10/79;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 11/26/04;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 11/26/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283006</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 218;	current medication: Sulphasalazine Asprin Metoprolol Atorvastatin;	birth date: 9/27/24;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/58;	diagnosis date: 1/1/58;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/3/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/3/04;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Breast cancer;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283007</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 220;	current medication: Asacol 800mg BFZ 2.5mg Metformin Simvastatin;	birth date: 6/28/48;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/10/95;	diagnosis date: 3/25/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/10/04;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 12/10/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/90;	smoking amount: 5-14;	other illnesses: Type 2 DM.;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283008</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 223;	current medication: Prednisolone 20mg Asacol 2.4g;	birth date: 1/18/44;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/04;	diagnosis date: 3/15/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 12/16/04;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 12/16/04;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: unknown;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283009</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 224;	current medication: Salazopyrin BFZ Losartan Thyroxine Doxazosin;	birth date: 2/21/38;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/77;	diagnosis date: 1/1/77;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 12;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/4/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: Hypertension Hashimoto's Thyroditis;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283010</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 225;	current medication: Asacol;	birth date: 5/30/76;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/03;	diagnosis date: 6/2/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 1/6/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 1/6/05;	followup rectum: BOTH;	followup recto sigmoid: unknown;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/99;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283011</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 233;	current medication: Asacol 1.2g Asprin 75mg Amilodipine 10mg;	birth date: 2/2/29;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/92;	diagnosis date: 1/1/92;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/1/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/1/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 3/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/86;	smoking amount: 15-24;	other illnesses: MI 1986, Prostate cancer 1994;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283012</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 234;	current medication: Aza 150mg Atenolol Atorvastatin BFZ Clopidogril;	birth date: 9/29/46;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/1/88;	diagnosis date: 9/29/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 2/3/05;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/3/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/31/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: IHD Angina;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283013</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 234;	current medication: Aza 150mg Atenolol Atorvastatin BFZ Clopidogril;	birth date: 9/29/46;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/1/88;	diagnosis date: 9/29/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 2/3/05;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/3/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/31/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: IHD Angina;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283014</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 234;	current medication: Aza 150mg Atenolol Atorvastatin BFZ Clopidogril;	birth date: 9/29/46;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/1/88;	diagnosis date: 9/29/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 2/3/05;	indictation for procedure: ;	ucss: 4;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 2/3/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/31/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: IHD Angina;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283015</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 236;	current medication: None;	birth date: 11/20/53;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/05;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/18/05;	indictation for procedure: ;	ucss: 15;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 2/18/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: 1/1/71;	smoking stop date: ;	smoking amount: 15-24;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: terminal ileum;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed terminal ileum</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283016</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 237;	current medication: Omep 20mg Losartan 50mg Bisoprolol 5mg Prav 40mg;	birth date: 11/12/28;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 10/1/95;	diagnosis date: 11/13/95;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 2/18/05;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/5/03;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 5/30/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: 1/1/50;	smoking stop date: 1/1/52;	smoking amount: 0-4;	other illnesses: Hypercholesteremia Prev CABG;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283017</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 239;	current medication: Asacol Fybogel Amitriptiline;	birth date: 4/10/41;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 12/1/63;	diagnosis date: 12/12/64;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/3/05;	indictation for procedure: ;	ucss: 6;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 1;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 3/3/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 6/1/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283018</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 240;	current medication: Asacol 800mg BD;	birth date: 1/10/59;	gender: M;	ethnicity: ASIAN;	symptoms onset date: 8/2/04;	diagnosis date: 12/14/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/3/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/3/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283019</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 240;	current medication: Asacol 800mg BD;	birth date: 1/10/59;	gender: M;	ethnicity: ASIAN;	symptoms onset date: 8/2/04;	diagnosis date: 12/14/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/3/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/3/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/31/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283020</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 242;	current medication: Salazopyrin Folic acid;	birth date: 10/18/39;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/75;	diagnosis date: 1/1/75;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/22/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 3/22/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 7/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/95;	smoking amount: 0-4;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283021</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 242;	current medication: Salazopyrin Folic acid;	birth date: 10/18/39;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/75;	diagnosis date: 1/1/75;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/22/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 3/22/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 7/7/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/95;	smoking amount: 0-4;	other illnesses: None;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283022</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 244;	current medication: Seratide Bricanyl BFZ;	birth date: 1/29/55;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/03;	diagnosis date: 6/16/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/29/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/29/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 6/1/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/94;	smoking amount: 15-24;	other illnesses: Asthma Hypertension;	disease: UC;	run_date: 8-9-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283023</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 244;	current medication: Seratide Bricanyl BFZ;	birth date: 1/29/55;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/03;	diagnosis date: 6/16/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/29/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/29/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 6/1/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/94;	smoking amount: 15-24;	other illnesses: Asthma Hypertension;	disease: UC;	run_date: 8-9-01;	anatomic_location: descending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283024</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 244;	current medication: Seratide Bricanyl BFZ;	birth date: 1/29/55;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/03;	diagnosis date: 6/16/03;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 3/29/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 3/29/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 6/1/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/94;	smoking amount: 15-24;	other illnesses: Asthma Hypertension;	disease: UC;	run_date: 8-9-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283025</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 250;	current medication: Asacol 2.4g/d;	birth date: 1/27/58;	gender: M;	ethnicity: ASIAN;	symptoms onset date: 1/1/94;	diagnosis date: 5/30/94;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/29/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 11;	igr2230: 11;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 4/29/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/95;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283026</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 250;	current medication: Asacol 2.4g/d;	birth date: 1/27/58;	gender: M;	ethnicity: ASIAN;	symptoms onset date: 1/1/94;	diagnosis date: 5/30/94;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/29/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 11;	igr2198: 11;	igr2230: 11;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 4/29/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/95;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283027</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 253;	current medication: Asacol 800mg BD;	birth date: 3/14/58;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 8/24/97;	diagnosis date: 9/4/97;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/24/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 5/24/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/3/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283028</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 253;	current medication: Asacol 800mg BD;	birth date: 3/14/58;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 8/24/97;	diagnosis date: 9/4/97;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/24/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 5/24/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/3/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283029</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 253;	current medication: Asacol 800mg BD;	birth date: 3/14/58;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 8/24/97;	diagnosis date: 9/4/97;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/24/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 5/24/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/3/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283030</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 254;	current medication: Asacol 800mg TDS, Predfoam;	birth date: 7/25/59;	gender: F;	ethnicity: ASIAN;	symptoms onset date: 1/1/00;	diagnosis date: 11/1/00;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/31/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 5/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283031</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 255;	current medication: Asacol 800mg BD;	birth date: 3/14/77;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/93;	diagnosis date: 1/1/93;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/31/05;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 5/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/01;	smoking amount: 0-4;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283032</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 255;	current medication: Asacol 800mg BD;	birth date: 3/14/77;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/93;	diagnosis date: 1/1/93;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/31/05;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 5/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/01;	smoking amount: 0-4;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283033</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 255;	current medication: Asacol 800mg BD;	birth date: 3/14/77;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/93;	diagnosis date: 1/1/93;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 5/31/05;	indictation for procedure: ;	ucss: 0;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 5/31/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/01;	smoking amount: 0-4;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283034</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 257;	current medication: 6MP 50mg;	birth date: 5/16/64;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/2/05;	indictation for procedure: ;	ucss: 7;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/2/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 9/14/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 2/1/05;	smoking amount: 0-4;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283035</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 257;	current medication: 6MP 50mg;	birth date: 5/16/64;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: ;	diagnosis date: ;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: unknown;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/2/05;	indictation for procedure: ;	ucss: 7;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: unknown;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/2/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 9/14/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 2/1/05;	smoking amount: 0-4;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283036</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 258;	current medication: Azathioprine 200mg Pentaza 1g TDS;	birth date: 10/26/64;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 6/1/87;	diagnosis date: 6/1/88;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/7/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/7/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283037</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 259;	current medication: pentaza 2g D;	birth date: 9/20/78;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 8/1/03;	diagnosis date: 1/13/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/7/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/7/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/03;	smoking amount: 5-14;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283038</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 259;	current medication: pentaza 2g D;	birth date: 9/20/78;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 8/1/03;	diagnosis date: 1/13/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/7/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/7/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 1/1/03;	smoking amount: 5-14;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283039</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 261;	current medication: Asacol 800mg BD;	birth date: 1/7/57;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/98;	diagnosis date: 1/1/98;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/14/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 2;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283040</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 261;	current medication: Asacol 800mg BD;	birth date: 1/7/57;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/98;	diagnosis date: 1/1/98;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/14/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 2;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283041</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 261;	current medication: Asacol 800mg BD;	birth date: 1/7/57;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/98;	diagnosis date: 1/1/98;	joint problems: FALSE;	uc flare up: FALSE;	family history: TRUE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/14/05;	indictation for procedure: ;	ucss: 2;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 2;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/14/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283042</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 263;	current medication: Azathioprine 75mg Fosomax 70mg;	birth date: 11/9/58;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/00;	diagnosis date: 6/1/00;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 7/8/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 7/8/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283043</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 263;	current medication: Azathioprine 75mg Fosomax 70mg;	birth date: 11/9/58;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/00;	diagnosis date: 6/1/00;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: TRUE;	procedure date: 7/8/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 7/8/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283044</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 265;	current medication: Pentaza 500mg TDS;	birth date: 8/17/71;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/5/04;	diagnosis date: 3/22/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/19/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 7/19/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 0-4;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283045</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 265;	current medication: Pentaza 500mg TDS;	birth date: 8/17/71;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/5/04;	diagnosis date: 3/22/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/19/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 7/19/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 0-4;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283046</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 265;	current medication: Pentaza 500mg TDS;	birth date: 8/17/71;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 2/5/04;	diagnosis date: 3/22/04;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/19/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 7/19/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 0-4;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283047</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 267;	current medication: Mesalazine 800mg TDS;	birth date: 8/16/74;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/05;	diagnosis date: 5/10/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 8/15/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 9/20/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 9/30/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 5/1/03;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283048</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 267;	current medication: Mesalazine 800mg TDS;	birth date: 8/16/74;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 5/1/05;	diagnosis date: 5/10/05;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 8/15/05;	indictation for procedure: ;	ucss: 1;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 9/20/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 9/30/05;	category: DISEASE IN REMISSION;	smoking status: ex;	smoking start date: ;	smoking stop date: 5/1/03;	smoking amount: 5-14;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283049</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 249;	current medication: Azathioprine 150mg Salazopyrine;	birth date: 1/12/60;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/90;	diagnosis date: 3/24/90;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/8/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 4/8/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283050</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 249;	current medication: Azathioprine 150mg Salazopyrine;	birth date: 1/12/60;	gender: M;	ethnicity: CAUCASIAN;	symptoms onset date: 3/1/90;	diagnosis date: 3/24/90;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 4/8/05;	indictation for procedure: ;	ucss: 3;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 12;	igr2198: 12;	igr2230: 12;	octn1: 12;	octn2: 12;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 12;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 4/8/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 5/30/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: None;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283051</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 260;	current medication: asacol 800mg TDS Asprin coproxamol;	birth date: 1/1/54;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/1/79;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/9/05;	indictation for procedure: ;	ucss: 12;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/9/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 5-14;	other illnesses: Arthritis Depression Alcohol excess;	disease: UC;	run_date: 11-15-01;	anatomic_location: ascending colon;	inflammation_status: Uninflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Uninflamed ascending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283052</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 260;	current medication: asacol 800mg TDS Asprin coproxamol;	birth date: 1/1/54;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/1/79;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/9/05;	indictation for procedure: ;	ucss: 12;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/9/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 5-14;	other illnesses: Arthritis Depression Alcohol excess;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283053</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 260;	current medication: asacol 800mg TDS Asprin coproxamol;	birth date: 1/1/54;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/79;	diagnosis date: 1/1/79;	joint problems: FALSE;	uc flare up: TRUE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 6/9/05;	indictation for procedure: ;	ucss: 12;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: TRUE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: unknown;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 6/9/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: DISEASE IN REMISSION;	smoking status: current;	smoking start date: ;	smoking stop date: ;	smoking amount: 5-14;	other illnesses: Arthritis Depression Alcohol excess;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283054</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 262;	current medication: Asacol 2.4g co-codamol;	birth date: 7/17/43;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/87;	diagnosis date: 1/1/87;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 7/5/05;	indictation for procedure: ;	ucss: 6;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 7/5/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: descending colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed descending colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283055</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 262;	current medication: Asacol 2.4g co-codamol;	birth date: 7/17/43;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/87;	diagnosis date: 1/1/87;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: YES;	aza tolerant: TRUE;	aza at present: FALSE;	procedure date: 7/5/05;	indictation for procedure: ;	ucss: 6;	calprotectin: 0;	esr: 0;	crp: 0;	hb: 0;	wcc: 0;	neutrophils: 0;	albumin: 0;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: ;	igr2198: ;	igr2230: ;	octn1: ;	octn2: ;	nod 702: ;	nod 908: ;	dlg5 133a: ;	nod 1007 fs: ;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: unknown;	diagnosis hep flex: unknown;	diagnosis total: unknown;	last followup date: 7/5/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: unknown;	followup hep flex: unknown;	followup total: unknown;	casenote review date: 8/15/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: none;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL1708</value>
            <value column="1">GSM283056</value>
            <value column="2">GSE11223</value>
            <value column="3">patient: 266;	current medication: Prednisolone ciproxin mesalazine fosomax Fe SO4;	birth date: 8/12/40;	gender: F;	ethnicity: CAUCASIAN;	symptoms onset date: 1/1/93;	diagnosis date: 1/1/93;	joint problems: FALSE;	uc flare up: FALSE;	family history: FALSE;	aza treated: NO;	aza tolerant: FALSE;	aza at present: FALSE;	procedure date: 7/22/05;	indictation for procedure: ;	ucss: 6;	calprotectin: 700;	esr: 0;	crp: 20;	hb: 93;	wcc: 17;	neutrophils: 16;	albumin: 23;	blood obtained: FALSE;	ibd affected relatives: 0;	igr2096: 0;	igr2198: 11;	igr2230: 11;	octn1: 11;	octn2: 11;	nod 702: 11;	nod 908: 11;	dlg5 133a: 11;	nod 1007 fs: 11;	diagnosis rectum: BOTH;	diagnosis recto sigmoid: BOTH;	diagnosis splen flex: BOTH;	diagnosis hep flex: BOTH;	diagnosis total: BOTH;	last followup date: 7/22/05;	followup rectum: BOTH;	followup recto sigmoid: BOTH;	followup splen flex: BOTH;	followup hep flex: BOTH;	followup total: BOTH;	casenote review date: 8/15/05;	category: FAILURE OF THERAPY;	smoking status: never;	smoking start date: ;	smoking stop date: ;	smoking amount: unknown;	other illnesses: COPD-Previous severe pneumonia;	disease: UC;	run_date: 11-15-01;	anatomic_location: sigmoid colon;	inflammation_status: Inflamed</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample type: total RNA from 10 human cell lines</value>
            <value column="6">UC Inflamed sigmoid colon</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434627</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours;	cell line: HeLa</value>
            <value column="6">6h time point, biological replicate 1 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434628</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours;	cell line: HeLa</value>
            <value column="6">6h time point, biological replicate 1 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434629</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours;	cell line: HeLa</value>
            <value column="6">6h time point, biological replicate 2 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434630</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours;	cell line: HeLa</value>
            <value column="6">6h time point, biological replicate 2 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434631</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours;	cell line: HeLa</value>
            <value column="6">6h time point, biological replicate 3 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434632</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours;	cell line: HeLa</value>
            <value column="6">6h time point, biological replicate 3 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434633</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours;	cell line: HeLa</value>
            <value column="6">24h time point, biological replicate 1 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434634</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours;	cell line: HeLa</value>
            <value column="6">24h time point, biological replicate 1 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434635</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours;	cell line: HeLa</value>
            <value column="6">24h time point, biological replicate 2 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434636</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours;	cell line: HeLa</value>
            <value column="6">24h time point, biological replicate 2 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434637</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours;	cell line: HeLa</value>
            <value column="6">24h time point, biological replicate 3 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM434638</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours;	cell line: HeLa</value>
            <value column="6">24h time point, biological replicate 3 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434695</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours</value>
            <value column="6">6h time point, biological replicate 1 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434696</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours</value>
            <value column="6">6h time point, biological replicate 1 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434697</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours</value>
            <value column="6">6h time point, biological replicate 2 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434698</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours</value>
            <value column="6">6h time point, biological replicate 2 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434699</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours</value>
            <value column="6">6h time point, biological replicate 3 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434700</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 6 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 6 additional hours</value>
            <value column="6">6h time point, biological replicate 3 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434701</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours</value>
            <value column="6">24h time point, biological replicate 1 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434702</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours</value>
            <value column="6">24h time point, biological replicate 1 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434703</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours</value>
            <value column="6">24h time point, biological replicate 2 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434704</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours</value>
            <value column="6">24h time point, biological replicate 2 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434705</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours</value>
            <value column="6">24h time point, biological replicate 3 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL8950</value>
            <value column="1">GSM434706</value>
            <value column="2">GSE17403</value>
            <value column="3">treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours;	cell line: HeLa</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: HeLa;	treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours</value>
            <value column="6">24h time point, biological replicate 3 of 3. Technical replicate 2 of 2. HeLa cells treated with EGF compared to untreated controls.</value>
        </row>
        <row>
            <value column="0">GPL6848</value>
            <value column="1">GSM438281</value>
            <value column="2">GSE17594</value>
            <value column="3">nod2 genotype: WT/WT;	nod2 risk alleles (r = risk allele, nr= not risk allele): NOD2nr;	smoking history: no smoking history prior;	tnf infusion: single anti-TNF infusion 18 months prior;	disease state: Crohn's disease;	tissue: unaffected ileum</value>
            <value column="4">Homo sapiens</value>
            <value column="5">nod2 genotype: WT/WT;	nod2 risk alleles (r = risk allele, nr= not risk allele): NOD2 nr control patient;	smoking history: no smoking history prior;	tnf infusion: no anti-TNF medication history prior;	disease state: control;	tissue: unaffected ileum</value>
            <value column="6">n/a</value>
        </row>
        <row>
            <value column="0">GPL6848</value>
            <value column="1">GSM438282</value>
            <value column="2">GSE17594</value>
            <value column="3">nod2 genotype: WT/WT;	nod2 risk alleles (r = risk allele, nr= not risk allele): NOD2nr;	smoking history: no smoking history prior;	tnf infusion: single anti-TNF infusion 18 months prior;	disease state: Crohn's disease;	tissue: affected ileum</value>
            <value column="4">Homo sapiens</value>
            <value column="5">nod2 genotype: WT/WT;	nod2 risk alleles (r = risk allele, nr= not risk allele): NOD2 nr control patient;	smoking history: no smoking history prior;	tnf infusion: no anti-TNF medication history prior;	disease state: control;	tissue: unaffected ileum</value>
            <value column="6">n/a</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM499398</value>
            <value column="2">GSE19992</value>
            <value column="3">cell line: ADDP;	sample type: Induced resistance to cisplatin. Weekly exposure of 1hrs at 50 M for 6 months</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: A2780;	sample type: parental cell line to ADDP</value>
            <value column="6">NA</value>
        </row>
        <row>
            <value column="0">GPL10423</value>
            <value column="1">GSM544143</value>
            <value column="2">GSE21882</value>
            <value column="3">status: Alive;	tissue: fresh frozen tumour</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample_type: reference</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL10423</value>
            <value column="1">GSM544151</value>
            <value column="2">GSE21882</value>
            <value column="3">status: Alive;	tissue: fresh frozen tumour</value>
            <value column="4">Homo sapiens</value>
            <value column="5">sample_type: reference</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580047</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 02;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580048</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 03;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580049</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 04;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580050</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 05;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580051</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 06;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580052</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 01;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580054</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 01;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580055</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 02;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580056</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 03;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580057</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 04;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580058</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 05;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580059</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 06;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580060</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 07;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580061</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 08;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580062</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 09;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580063</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 10;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580064</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 11;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580065</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 12;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580066</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 13;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580067</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 14;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580068</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 15;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580069</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 16;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580070</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 17;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580071</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 18;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580072</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 19;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580073</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 20;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580074</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 21;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580076</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 22;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580077</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 23;	baseline/follow-up: baseline;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580078</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 02;	baseline/follow-up: follow up;	disease status: Squamous Cell Cancer;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580079</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 03;	baseline/follow-up: follow up;	disease status: CIS;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580080</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 04;	baseline/follow-up: follow up;	disease status: Severe Dysplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580081</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 05;	baseline/follow-up: follow up;	disease status: CIS;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580082</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 06;	baseline/follow-up: follow up;	disease status: Severe Dysplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580083</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Case 01;	baseline/follow-up: follow up;	disease status: Squamous Cell Cancer;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580084</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 02;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580085</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 03;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580086</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 04;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580087</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 05;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580088</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 06;	baseline/follow-up: follow up;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580089</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 07;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580090</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 08;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: female</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580091</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 09;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580092</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 10;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580093</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 11;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580094</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 12;	baseline/follow-up: follow up;	disease status: Normal;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: male</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580095</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 20;	baseline/follow-up: follow up;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580096</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 21;	baseline/follow-up: follow up;	disease status: Squamous Metaplasia;	tissue: bronchial</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580098</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 22;	baseline/follow-up: follow up;	disease status: Squamous Metaplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL8841</value>
            <value column="1">GSM580099</value>
            <value column="2">GSE23644</value>
            <value column="3">case number: Control 23;	baseline/follow-up: follow up;	disease status: Severe Dysplasia;	tissue: bronchial;	gender: male</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: blood;	gender: female</value>
            <value column="6">Pooled DNA from the blood of 18 healthy individuals was used as reference in the aCGH experiments; across array CGH comparisons were made as described by Buffart et al, Genes, Chromosomes description =  Cancer 2008, 47(11): 994-1004</value>
        </row>
        <row>
            <value column="0">GPL2879</value>
            <value column="1">GSM702539</value>
            <value column="2">GSE28403</value>
            <value column="3">disease state: Advanced prostate cancer;	treatment: Androcur (3 months);	tissue: prostate cancer tumor</value>
            <value column="4">Homo sapiens</value>
            <value column="5">reference: Promega normal male genomic DNA</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL2873</value>
            <value column="1">GSM702540</value>
            <value column="2">GSE28403</value>
            <value column="3">disease state: Advanced prostate cancer;	treatment: Androcur (1 month);	tissue: prostate cancer tumor</value>
            <value column="4">Homo sapiens</value>
            <value column="5">reference: Promega normal male genomic DNA</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018078</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: none</value>
            <value column="6">Biological replicate 1 of 4.;	ch1: T-47D cells irradiated at low-dose rate, harvested after 2 months.;	ch2: Control T-47D cells, untreated, harvested after several passages.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018079</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: none</value>
            <value column="6">Biological replicate 2 of 4.;	ch1: T-47D cells irradiated at low-dose rate, harvested after 2 months.;	ch2: Control T-47D cells, untreated, harvested after several passages.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018080</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: none</value>
            <value column="6">Biological replicate 3 of 4.;	ch1: T-47D cells irradiated at low-dose rate, harvested after 2 months.;	ch2: Control T-47D cells, untreated, harvested after several passages.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018081</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: none</value>
            <value column="6">Biological replicate 4 of 4.;	ch1: T-47D cells irradiated at low-dose rate, harvested after 2 months.;	ch2: Control T-47D cells, untreated, harvested after several passages.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018086</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated with 0.3 Gy at 35 Gy/h 24 h before harvest</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="6">Biological replicate 1 of 3.;	ch1: T-47D cells irradiated at high-dose rate, harvested after 24 h.;	ch2: T-47D cells irradiated at low-dose rate, harvested after 2 months.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018087</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated with 0.3 Gy at 35 Gy/h 24 h before harvest</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="6">Biological replicate 2 of 3.;	ch1: T-47D cells irradiated at high-dose rate, harvested after 24 h.;	ch2: T-47D cells irradiated at low-dose rate, harvested after 2 months.</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1018088</value>
            <value column="2">GSE41483</value>
            <value column="3">cell line: T-47D;	cell type: breast cancer cells;	treatment: Irradiated with 0.3 Gy at 35 Gy/h 24 h before harvest</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: T-47D;	cell type: breast cancer cells;	cell treatment: Irradiated 1h at 0.3 Gy/h, then cultured for 2 months</value>
            <value column="6">Biological replicate 3 of 3.;	ch1: T-47D cells irradiated at high-dose rate, harvested after 24 h.;	ch2: T-47D cells irradiated at low-dose rate, harvested after 2 months.</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312353</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312354</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312355</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312356</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312357</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312358</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312359</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312360</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312361</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312362</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312363</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312364</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312365</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312366</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312367</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312368</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312369</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312370</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312371</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312372</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312373</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312374</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312375</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312376</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312377</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312378</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312379</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312380</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312381</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312382</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312383</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MALT01_to_MALT31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312384</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 9.41666666666667;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312385</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.333333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312386</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.91666666666667;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312387</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.75;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312388</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312389</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312390</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.416666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312391</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.33333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312392</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312393</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.25;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312394</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.25;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312395</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 11.75;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312396</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.166666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312397</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.83333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312398</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.0833333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312399</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.08333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312400</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312401</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.75;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312402</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 14.25;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312403</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 9;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312404</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.5;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312405</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.16666666666667;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312406</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.5;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312407</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312408</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.416666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Burkitt_lymphoma01_to_26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312409</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.96164383561644;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312410</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.293150685;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312411</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.95068493150685;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312412</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.265753425;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312413</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.57808219178082;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312414</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.51506849315069;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312415</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.36164383561644;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312416</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.205479452;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312417</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 3.72054794520548;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312418</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.18356164383562;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_5.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312419</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.94520547945205;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_5.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312420</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312421</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.61917808219178;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312422</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.47945205479452;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_4.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312423</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.41095890410959;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_5.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312424</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.20547945205479;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312425</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.18904109589041;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_5.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312426</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 21;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.0986301369863;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312427</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.76164383561644;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312428</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 16;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.68767123287671;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312429</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.66849315068493;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312430</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 21;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.61095890410959;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312431</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.40821917808219;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312432</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.34246575342466;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312433</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.27397260273973;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312434</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.17534246575342;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312435</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.16712328767123;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312436</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.12054794520548;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312437</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.08219178082192;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312438</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 19;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.03835616438356;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312439</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.03013698630137;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312440</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 15;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.96986301369863;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312441</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 15;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.964383561643836;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_4.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312442</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.819178082191781;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_5.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312443</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.802739726;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312444</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.767123287671233;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312445</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.745205479452055;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312446</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 14;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.723287671232877;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312447</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.594520547945205;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_4.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312448</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 17;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.526027397260274;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312449</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.504109589;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312450</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.493150684931507;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312451</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.454794520547945;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312452</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.284931506849315;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312453</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.26849315;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312454</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.254794;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312455</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.10958904109589;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312456</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 20;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.0821917808219178;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_4.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312457</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 16;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 11.8958904109589;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312458</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 15;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 10.4931506849315;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312459</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 20;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 9.47671232876712;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312460</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 8.65479452054795;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312461</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 8.31780821917808;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312462</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 8.21095890410959;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312463</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.75890410958904;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312464</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.569863014;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312465</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 21;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 7.44383561643836;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312466</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 7.36164383561644;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312467</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.13150684931507;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312468</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.84109589;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312469</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 6.71506849315069;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312470</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 16;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.59178082191781;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312471</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.31232876712329;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312472</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.29041095890411;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312473</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.25479452054795;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312474</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.03835616438356;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312475</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.56164383561644;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312476</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.36438356164384;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312477</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.34794520547945;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312478</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 5.18356164383562;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312479</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 5.142465753;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312480</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 17;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 4.44109589041096;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312481</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.24931506849315;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312482</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.15890410958904;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312483</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.04657534246575;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312484</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.63013698630137;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312485</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.830136986;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312486</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.74794520547945;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312487</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.70958904109589;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312488</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.50958904109589;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_4.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312489</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.32054794520548;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312490</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.2986301369863;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312491</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.2383;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312492</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.93150684931507;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312493</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.70958904109589;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312494</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.69315068493151;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312495</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.67945205479452;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312496</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.54794520547945;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312497</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.40821917808219;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_4.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312498</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.26027397260274;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312499</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.05753424657534;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312500</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.04109589041096;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312501</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.460273973;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312502</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.383561643835616;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312503</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 14;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312504</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 23;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312505</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 28;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312506</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312507</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312508</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 15;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312509</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 23;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312510</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312511</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312512</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312513</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312514</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312515</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312516</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312517</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312518</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312519</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 16;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312520</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312521</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312522</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312523</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312524</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 26;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312525</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: DLBCL_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312526</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.51780821917808;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312527</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 9.40821917808219;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312528</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.31506849315068;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312529</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.32054794520548;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312530</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 12.6027397260274;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312531</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.22191780821918;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312532</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312533</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312534</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312535</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312536</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312537</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312538</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312539</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312540</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312541</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312542</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312543</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312544</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.14520547945205;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312545</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.25753424657534;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312546</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312547</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312548</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312549</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312550</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312551</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.19178082191781;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312552</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.02191780821918;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312553</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 14;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.45753424657534;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312554</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.14794520547945;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312555</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.84109589041096;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312556</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 9.83561643835616;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312557</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.627397260273973;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312558</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.57534246575342;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312559</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.33972602739726;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312560</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 6.4958904109589;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312561</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312562</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312563</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312564</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312565</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312566</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312567</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.82191780821918;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312568</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312569</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 8.04109589041096;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312570</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.24383561643836;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312571</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312572</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.44657534246575;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312573</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.98904109589041;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312574</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.99178082191781;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312575</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 10.572602739726;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312576</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312577</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 11.9150684931507;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312578</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 16.3287671232877;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312579</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.66027397260274;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312580</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312581</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312582</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312583</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312584</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 26;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312585</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312586</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312587</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 13.9945205479452;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312588</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312589</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312590</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312591</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312592</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312593</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312594</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312595</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312596</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.0794520547945206;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_2.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312597</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 25;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312598</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312599</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.4;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_1.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312600</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 20;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312601</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312602</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312603</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312604</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: Follicular_lymphoma_3.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312605</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.16712328767123;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312606</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.76986301369863;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312607</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 14;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.336986301369863;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312608</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.74246575342466;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312609</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.71780821917808;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312610</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 10;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.41369863013699;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312611</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 3.29041095890411;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312612</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312613</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.18356164383562;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312614</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 7.07671232876712;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312615</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: null;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.92328767123288;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312616</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.857534246575342;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312617</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.873972602739726;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312618</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.16164383561644;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312619</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.52876712328767;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312620</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 14.3095890410959;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312621</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.40821917808219;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312622</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 8.72876712328767;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312623</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.03561643835616;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312624</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.917808219178082;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312625</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.03013698630137;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312626</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 17;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.421917808219178;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312627</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 38;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.62465753424658;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312628</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.983561643835616;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312629</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.43013698630137;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312630</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.95342465753425;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312631</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 19;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.59178082191781;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312632</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 7;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.51506849315069;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312633</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 17;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 5.16164383561644;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: MCL01_to_MCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312634</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.33333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL01.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312635</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 9;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL02.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312636</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL03.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312637</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL04.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312638</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.0833333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL05.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312639</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.833333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL06.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312640</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 6.66666666666667;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL07.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312641</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.41666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL08.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312642</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.25;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL09.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312643</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.83333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL10.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312644</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.66666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL11.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312645</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL12.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312646</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.08333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL13.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312647</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 5.5;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL14.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312648</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.75;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL15.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312649</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 0;	with or without clonal heterogeneity: NA;	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.5;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL16.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312650</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.25;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL17.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312651</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 4.25;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL18.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312652</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.58333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL19.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312653</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.833333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL20.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312654</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL21.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312655</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 4;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.333333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL22.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312656</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 22;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.91666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL23.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312657</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 1;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.33333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL24.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312658</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 3;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 1.25;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL25.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312659</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 2.83333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL26.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312660</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.75;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL27.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312661</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.58333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL28.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312662</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.0833333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL29.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312663</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 5;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.5;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL30.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312664</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 2;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.25;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL31.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312665</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 6;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL32.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312666</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 8;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.25;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL33.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312667</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 13;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.41666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL34.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312668</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 11;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL35.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312669</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.583333333333333;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL36.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312670</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL37.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312671</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 3.75;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL38.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312672</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.916666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL39.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312673</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.166666666666667;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL40.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312674</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 12;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 7.25;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL41.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312675</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 23;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 2.41666666666667;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL42.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312676</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL43.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312677</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 21;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: null;	dead or alive at the end of follow-up: null</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL44.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312678</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 4.16666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL45.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312679</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 29;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.0833333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL46.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312680</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 9;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): 0;	follow up years: 0.666666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL47.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312681</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 21;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.16666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL48.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312682</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 25;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.166666666666667;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL49.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312683</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 18;	with or without clonal heterogeneity: clonal heterogeneity (-);	international prognostic index: high / high intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): loss / deletion;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 1.83333333333333;	dead or alive at the end of follow-up: Dead</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL50.txt</value>
        </row>
        <row>
            <value column="0">GPL18197</value>
            <value column="1">GSM1312684</value>
            <value column="2">GSE54303</value>
            <value column="3">total number of genomic aberrations: 20;	with or without clonal heterogeneity: clonal heterogeneity (+);	international prognostic index: low / low intermediate;	genomic loss/deletion for 9p21.3 (cdkn2a locus): 0;	genomic loss for 17p13.1 (tp53 locus): loss;	follow up years: 0.25;	dead or alive at the end of follow-up: Alive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">gender: male</value>
            <value column="6">file with raw data for this sample: PTCL51.txt</value>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1328994</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: JQ1 followed by DHT;	cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ERG fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1328995</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: JQ1 followed by DHT;	cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ERG fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1328996</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: MDV followed by DHT;	cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ERG fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1328997</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: MDV followed by DHT;	cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ERG fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1328998</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: Bic. followed by DHT;	cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ERG fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1328999</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: Bic. followed by DHT;	cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ERG fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: VCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1329002</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: JQ1 followed by DHT;	cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ETV1 fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1329003</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: JQ1 followed by DHT;	cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ETV1 fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1329004</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: MDV followed by DHT;	cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ETV1 fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1329005</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: MDV followed by DHT;	cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ETV1 fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1329006</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: Bic. followed by DHT;	cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ETV1 fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM1329007</value>
            <value column="2">GSE55063,GSE55064</value>
            <value column="3">treatment: Bic. followed by DHT;	cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non;	genotype/variation: AR positive, ETV1 fusion positive</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: LNCaP;	cell type: prostate cancer cells;	transduced with: non</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL6480</value>
            <value column="1">GSM1396357</value>
            <value column="2">GSE57885</value>
            <value column="3">cell line: PC3 metastatic prostate cancer cell line;	treatment: PC3 cells 72 hours following the transfection with a siRNA targeting Ago1 (siAgo1);	genotype/variation: Ago1 knockdown</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: PC3 metastatic prostate cancer cell line;	treatment: PC3 cells 72 hours following the transfection with a scramble siRNA (siGL3);	genotype/variation: control</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL6480</value>
            <value column="1">GSM1396358</value>
            <value column="2">GSE57885</value>
            <value column="3">cell line: PC3 metastatic prostate cancer cell line;	treatment: PC3 cells 72 hours following the transfection with a scramble siRNA (siGL3);	genotype/variation: control</value>
            <value column="4">Homo sapiens</value>
            <value column="5">cell line: PC3 metastatic prostate cancer cell line;	treatment: PC3 cells 72 hours following the transfection with a siRNA targeting Ago1(siAgo1);	genotype/variation: Ago1 knockdown</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM988345</value>
            <value column="2">GSE40206</value>
            <value column="3">tissue: normal breast tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: tumor breast tissue;	patient id: 80T;	nod status: NOD-;	er status: ER-;	pr status: PR-;	her status: HER+;	er: 0;	pr: 0;	her: 3;	size: 2.2x2x2.5;	diag.: IDC - III with focal high grade DCIS, Margins fairly circumscribed, lymphocytic infiltration seen at the periphery;	skin: Free;	dsm: Close but free;	nodal status: 12/12 free;	last follow-up: 02.09.09;	last follow-up notes: NAD;	other relevant investigations: --------;	follow-up period: 3yr.2m</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL4133</value>
            <value column="1">GSM988347</value>
            <value column="2">GSE40206</value>
            <value column="3">tissue: normal breast tissues</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: tumor breast tissue;	patient id: 96T;	nod status: NOD-;	er status: ER0;	pr status: PR0;	her status: HER0;	er: 3+3;	pr: 3+2;	her: 2+;	size: 5x4x2.5;	diag.: IDC III  with infiltrating margins, and showing lymphocytic response.;	skin: --------;	dsm: Free;	nodal status: 10/10 free;	last follow-up: 1.04.11;	last follow-up notes: NAD (To continue with Tamoxifen);	other relevant investigations: --------;	follow-up period: 4yr.5m</value>
            <value column="6" null="true"/>
        </row>
        <row>
            <value column="0">GPL8366</value>
            <value column="1">GSM452338</value>
            <value column="2">GSE18097</value>
            <value column="3">tissue: fresh peripheral blood;	disease status: healthy donor with no history of autoimmune disease</value>
            <value column="4">Homo sapiens</value>
            <value column="5">tissue: fresh peripheral blood;	disease status: Rheumatoid arthritis patients fulfilling the 1987 revised classification criteria of the american college of rheumatology.;	therapy: oral corticosteroids for at least one month</value>
            <value column="6">Additional eligibility criteria: methotrexate (MTX) treatment; DAS28  3.2; and resistance to at least 2 DMARDs (MTX and anti-TNF included). For one month or more before the start of this study, every patient was given stable doses of oral corticosteroids and did not receive any intra-articular steroid injections.</value>
        </row>
</rows></results>